– Company Expects to Initiate a Phase 1 Study in Late 2020 – “We are excited to advance our ALN-HSD program to the clinic in partnership with Regeneron, particularly given the mass prevalence and high ...

- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer’s Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry’s First-Ever RNAi ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K.

Alnylam Pharmaceuticals, Inc. ALNY announced that it has filed a Clinical Trial Authorization (CTA) application to Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom to ...

Alnylam Pharmaceuticals, Inc. ALNY announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for the initiation of a phase ...